Scaling up GMP-grade dopaminergic cells for Parkinson's disease
1National Hospital for Neurology & Neurosurgery, UCL Institute of Neurology, Queen Square, London, UK.
Cell Stem Cell
|January 5, 2024
Abstract:
Stem cell therapy for Parkinson's disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park et al. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.


